BACKGROUND Experimental clinical studies have demonstrated that the addition of salmeterol to inhaled corticosteroids (ICSs) is superior to the addition of montelukast to ICSs. Observational research from real-world clinical practice is needed to confirm these results. OBJECTIVE The present study was designed to assess, in clinical practice, the comparative impact on health care utilization a...

Pulmonary fibrosis (PF) is an interstitial lung disease leading to scarring of the lung. There are several types as familial pulmonary fibrosis, idiopathic and others associated with non-specific
 
 pneumonia. The most common type which unknown cause. Lung causes changes in histology by disappearance parenchyma, replaced inflammatory infiltrate, mild thickening artery. management incl...

Introduction . One of the antileukotriene drugs for treatment bronchial asthma and allergic rhinitis with without polyposis is montelukast. The presented article presents results analysis effectiveness, safety impact on quality life patients, use singular, in various forms associated comorbid conditions. Aim study To assess effectiveness montelukast complex therapy patients diseases. Materials ...

Abstract Background/Aims Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, multisystemic, autoimmune vasculitis involving small to medium-sized blood vessels. It has well-established affiliation atopic syndromes, typically adult-onset asthma and sinusitis. More rare associations are linked drug side effects such as Montelukast. According the ‘American College of Rheumatology 1990’...

Results Case 1 A 15 year old girl with worsening asthma and rhinitis presented with a persistent 10x6 cm breast lump 6 months after starting Montelukast. Chest X-rays and CT scan were normal, maxillary sinuses congested, with absolute eosinophilia of 2.4 x 10/l, ESR normal, no proteinuria). On needle biopsy, dilated ducts contained necrotic eosinophilic debris, intense infiltrate of eosinophils...

Eosinophilic cystitis (EC) is a rare inflammatory disorder. We herein report a case of EC in an asthmatic female patient who had a recent exacerbation with none known allergen. She was administered montelukast sodium orally for four weeks and received complete remission. This medication was successfully discontinued after a three-month follow up period. This case report about successful treatme...

Background: The protective effects of Montelukast (Mont), as an anti-inflammatory drug, against cadmium-induced kidney cell damage have already been studied and identified. Since the significant part cadmium nephrotoxicity is caused by oxidative stress, this in vivo vitro study was conducted to investigate possible role antioxidant properties protection. Methods: In section, 42 rats were treate...

A rapid LC-MS/MS method was developed and partially validated for the quantitation of montelukast in spiked sheep plasma. A total run time of 1.5 min was achieved using a short monolithic column and employing a rapid gradient. Sample preparation involved protein precipitation with twofold acetonitrile by volume during which a deuterated internal standard (montelukast D-6) was incorporated. The ...

OBJECTIVES To determine the clinical effectiveness, tolerability and reliability of montelukast and to compare this drug with inhaled corticosteroids. METHODS We performed a randomized, 14-week, 2-period, prospective parallel group study. After a 2-week run-in period, patients received treatment for 12 weeks. Sixty-three clinically stable outpatients aged 8 to 14 years with a history of mild ...